(Q386119)

Statements

instance of

type of chemical entity

0 references

subclass of

protein

0 references

has use

medication

1 reference

title

Natalizumab (English)

stated in

DrugBank

language of work or name

English

publication date

17 November 2015

DrugBank ID

00108

image of molecular model or crystal lattice model

Natalizumab 4IRZ.png
2,048 × 2,048; 155 KB

depicts

space-filling model

0 references

defined daily dose

10 milligram

route of administration

parenteral route of administration

1 reference

reference URL

https://www.whocc.no/atc_ddd_index/?code=L04AA23

active ingredient in

Natalizumab Elan Pharma

1 reference

European Medicines Agency product number

EMEA/H/C/000624

reference URL

http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000624/human_med_000919.jsp

retrieved

22 March 2017

Tysabri

1 reference

European Medicines Agency product number

EMEA/H/C/000603

reference URL

http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000603/human_med_001119.jsp

retrieved

22 March 2017

World Health Organisation international non-proprietary name

natalizumab (English)

1 reference

stated in

ChEMBL

ChEMBL ID

CHEMBL1201607

language of work or name

English

title

Natalizumab (English)

retrieved

19 January 2016

side effect

headache

0 references

fatigue

0 references

arthralgia

0 references

urinary tract infection

0 references

lower respiratory tract infection

0 references

gastroenteritis

0 references

vaginitis

0 references

mental depression

0 references

nausea

0 references

medical condition treated

secondary progressive multiple sclerosis

1 reference

stated in

Drug Indications Extracted from FAERS

retrieved

2 October 2018

relapsing-remitting multiple sclerosis

1 reference

stated in

Drug Indications Extracted from FAERS

retrieved

2 October 2018

multiple sclerosis

1 reference

stated in

Drug Indications Extracted from FAERS

retrieved

2 October 2018

Crohn's disease

0 references

route of administration

intravenous infusion and defusion

0 references

legal status (medicine)

medical prescription

location

United States of America

start time

August 2023

applies to part

biosimilar

0 references

boxed warning

1 reference

reference URL

https://nctr-crs.fda.gov/fdalabel/ui/spl-summaries/criteria/343802

title

FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links. (English)

pregnancy category

Australian pregnancy category C

1 reference

imported from Wikimedia project

English Wikipedia

US pregnancy category C

1 reference

imported from Wikimedia project

English Wikipedia

has characteristic

biopharmaceutical

1 reference

title

Natalizumab (English)

stated in

DrugBank

language of work or name

English

publication date

17 November 2015

DrugBank ID

00108

subject has role

immunologic factor

1 reference

stated in

Medical Subject Headings

MeSH descriptor ID

D000069442

retrieved

15 March 2018

monoclonal antibody

1 reference

stated in

DrugBank

DrugBank ID

00108

language of work or name

English

title

Natalizumab (English)

publication date

17 November 2015

Identifiers